Plus Therapeutics Announces Date and Details for 2026 Annual Meeting of Stockholders: Key Deadlines for Shareholder Proposals and Director Nominations

Plus Therapeutics, Inc. (NASDAQ: PSTV) has released an important update regarding its upcoming 2026 Annual Meeting of Stockholders. The company’s Board of Directors has set the date for the meeting and issued revised deadlines for shareholders wishing to submit proposals or nominate directors—a development that could impact shareholder rights, governance, and potentially the company’s share price.

Key Highlights

• Annual Meeting Date: The 2026 Annual Meeting of Stockholders will be held virtually on Thursday, May 14, 2026, at 9:00 a.m. Eastern Time.
• Record Date: Only stockholders of record at the close of business on March 18, 2026 will be entitled to notice of, and to vote at, the 2026 Annual Meeting.
• Venue: The meeting will be held virtually by means of remote communication.
• Potential Changes: The company reserves the right to change the record date, as well as the date, time, and place of the meeting prior to the event.

Why This Matters to Shareholders

• Revised Deadlines for Shareholder Proposals and Director Nominations: Because the 2026 Annual Meeting is scheduled more than 30 days before the anniversary of the prior year’s meeting, previous deadlines for submitting shareholder proposals or director nominations (as stated in the 2025 proxy statement) are no longer applicable.
• New Submission Deadlines:
  • Rule 14a-8 Proposals: Shareholder proposals intended for inclusion in the proxy materials must be received at the following address no later than March 22, 2026:
    
    6420 Levit Green Boulevard, Suite 310, Houston, Texas 77021, Attention: Corporate Secretary
  • Director Nominations & Other Proposals: Pursuant to the Company’s Bylaws, stockholders seeking to bring business or nominate directors must deliver materials to the same address by 5:00 p.m. Eastern Time on Monday, March 22, 2026.
  • Universal Proxy Rule: To comply with Rule 14a-19, stockholders who intend to solicit proxies for director nominees (other than the Company’s nominees) must provide notice with all required information by March 22, 2026 as well.
• Compliance: All proposals and nominations must comply with Delaware law, SEC rules and regulations, and the Company’s Bylaws to be considered valid and timely.

Potential Price Sensitivity and Investor Impact

• Governance and Shareholder Rights: The rescheduling of the Annual Meeting and the announcement of new proposal and nomination deadlines represent significant governance developments. These changes may affect activist investors, long-term shareholders, and those wishing to influence the company’s direction or board composition.
• Corporate Actions: Any proposals or director nominations received by the deadline could shape the company’s governance for the coming year, including board structure and potential strategic direction. This could impact investor sentiment and, in turn, the share price.
• Potential for Shareholder Activism: The window for proposals and nominations is brief. Investors interested in influencing company policy, operations, or board composition should act promptly. Failure to meet the new deadline will result in exclusion from the 2026 proxy materials and annual meeting agenda.

Other Relevant Company Information

• Company Name: Plus Therapeutics, Inc.
• Trading Symbol: PSTV
• Exchange: Nasdaq Capital Market
• Common Stock: Par value \$0.001 per share

Important to Note: The company is not considered an emerging growth company as defined under SEC rules, and this 8-K filing does not amend previously filed reports or include written communications, soliciting material, or tender offers as defined under SEC regulations.

Action Items for Shareholders

1. Mark your calendar: May 14, 2026 for the Annual Meeting (virtual).
2. If you plan to submit a proposal or nominate a director, ensure delivery by March 22, 2026 to the Company’s Corporate Secretary at the Houston address listed above.
3. Review the Company’s Bylaws and SEC regulations to ensure compliance with all requirements for proposals or nominations.

Disclaimer: This article is for informational purposes only and does not constitute legal or investment advice. Investors should review official SEC filings and consult with their financial or legal advisors before making investment decisions. This summary is based on the company’s public disclosures as of March 12, 2026, and may not reflect subsequent changes or developments.

View PLUS THERAPEUTICS, INC. Historical chart here